Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy

Calidi Biotherapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Fast Track designation to its experimental therapy, CLD-201 SuperNova, for the treatment of glioblastoma.…

Continue Reading Calidi Biotherapeutics’ CLD-201 Secures FDA Fast Track for Innovative Glioblastoma Therapy